Karyopharm Therapeutics (KPTI) Tops Q3 EPS by 2c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q3 EPS of ($0.85), $0.02 better than the analyst estimate of ($0.87).

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Benchmark Starts Boyd Gaming (BYD) at Buy
• FedEx (FDX) PT Lowered to $424 at Bernstein SocGen Group